Table 2.

All-oral treatment for treatment-naïve HCV genotype 2 in the Asian-Pacific Region

Companies (regimen) [references]	Drug targets		Ribavirin	Duration of treatment (weeks)	SVR (%)
	NS5A	NS5B
Gilead Sciences [68–72]		Sofosbuvir (400 mg daily)	+	12	88–100
Bristol-Myers Squibb [73]	Daclatasvir (60 mg daily)	Sofosbuvir (400 mg daily)	±	24	96
Gilead Sciences [74]	Ledipasvir (90 mg daily)	Sofosbuvir (400 mg daily)	–	12	96
Gilead Sciences [75]	Velpatasvir (GS-5816) (25 or 100 mg)	Sofosbuvir (400 mg daily)	–	12	25 mg: 91 100 mg: 100